Oxygenta Pharmaceutical Limited has intimated BSE Limited about an upcoming board meeting scheduled for Tuesday, 10th November, 2026. The meeting will be held at the corporate office of the company.
The board will consider the following agenda items:
- Un-audited Financial results for the quarter and half year ended September 30, 2026
- Limited Review Report for the quarter ended September 30, 2026
- Any other business with the permission of the Chair
The disclosure is made pursuant to Regulation 29 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication is signed by Kumkum Bajaj, Company Secretary & Compliance Officer, and digitally dated November 5, 2026.
Financial Impact
Financial impact not quantified in the disclosure as this is an intimation of an upcoming board meeting where financial results will be considered.